Healthcare / Medical DevicesNasdaqGS
$9.27
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-9.1M · quality 42.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$375M
P/E
N/A
•EV/EBITDA
46.7x
↑ROE
-20.5%
↓Gross Margin
68.8%
↑Debt/Equity
0.40
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+2.6%
FCF CAGR
—
FCF margin
-0.2%
FCF / Net income
0.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $822.3M · net income $-92.2M · FCF $-1.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $822.3M | $822.3M | $799.5M | $746.6M | $460.7M | $464.5M | $406.6M | $460.0M | $453.0M | $433.8M | $409.8M | $396.5M | $402.3M | $397.6M | $440.2M | $435.5M | $462.6M | $545.6M |
| Net Income | $-92.2M | $-92.2M | $-126.0M | $-151.4M | $-19.7M | $-38.4M | $2.5M | $-28.5M | $13.8M | $6.2M | $3.1M | $-2.8M | $-8.5M | $-28.8M | $42.9M | $-17.7M | $44.3M | $24.5M |
| EBITDA | $9.9M | $9.9M | $-18.3M | $-79.5M | $15.7M | $21.3M | $24.3M | $5.9M | $48.8M | $60.9M | $41.9M | $30.2M | $40.0M | $11.6M | $93.2M | $29.8M | $88.1M | $86.2M |
| EPS | -2.33 | -2.33 | -3.30 | -4.12 | -0.98 | -1.95 | 0.13 | -1.51 | 0.72 | 0.34 | 0.17 | -0.15 | -0.46 | -1.54 | 2.21 | -0.97 | 2.47 | 1.42 |
| Gross Margin | 68.8% | 68.8% | 68.3% | 65.1% | 73.2% | 75.3% | 74.9% | 78.1% | 78.7% | 78.6% | 78.6% | 78.2% | 75.4% | 73.1% | 77.1% | 77.9% | 79.0% | 74.6% |
| Operating Margin | -10.0% | -10.0% | -9.7% | -19.0% | -6.3% | -1.8% | -1.5% | -4.1% | 6.6% | 9.4% | 5.1% | 2.3% | 4.3% | -2.8% | 17.0% | 1.5% | 14.3% | 11.7% |
| Net Margin | -11.2% | -11.2% | -15.8% | -20.3% | -4.3% | -8.3% | 0.6% | -6.2% | 3.0% | 1.4% | 0.7% | -0.7% | -2.1% | -7.2% | 9.7% | -4.1% | 9.6% | 4.5% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.40 | 0.40 | 0.36 | 0.20 | 0.06 | — | — | — | — | — | — | — | 0.00 | — | — | — | — | — |
| Current Ratio | 2.87 | 2.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-1.3M | $-1.3M | $-9.1M | $-107.8M | $-34.7M | $690000.00 | $58.8M | $13.0M | $36.3M | $24.3M | $42.6M | $16.4M | $33.1M | $42.3M | — | — | — | — |
| Returns | ||||||||||||||||||
| ROE | -20.5% | -20.5% | -25.0% | -25.3% | -5.9% | -11.4% | 0.7% | -8.7% | 4.1% | 2.1% | 1.2% | -1.0% | -2.8% | -9.7% | 12.0% | -6.3% | 14.7% | 10.2% |
| Valuation | ||||||||||||||||||
| EV/EBITDA | 46.67 | 46.67 | — | — | 24.02 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.82 | 0.82 | 1.31 | 0.78 | 1.20 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 2.9% | 2.9% | 7.1% | 62.1% | — | 14.2% | -11.6% | 1.5% | 4.4% | 5.9% | 3.4% | -1.4% | 1.2% | -9.7% | 1.1% | -5.8% | -15.2% | — |
| EPS Growth | 29.4% | 29.4% | 19.9% | -320.4% | — | -1600.0% | 108.6% | -309.7% | 111.8% | 100.0% | 213.3% | 67.4% | 70.1% | -169.7% | 327.8% | -139.3% | 73.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.30 → -2.33
Residual
-17.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.